Status and phase
Conditions
Treatments
About
The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
700 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Vertanical GmbH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal